logo
MIT, University of Colorado Denver, and Clue App Publish Largest Women's Health Study Documenting Air Pollution's Impact on Menstrual Cycles

MIT, University of Colorado Denver, and Clue App Publish Largest Women's Health Study Documenting Air Pollution's Impact on Menstrual Cycles

Yahoo16-05-2025

Analysis of 2.2 million menstrual cycles tracked in Clue shows connection between pollution exposure and reproductive health
CAMBRIDGE, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Researchers at MIT's Senseable City Lab and the University of Colorado Denver, in collaboration with the Clue app, have published the largest study of its kind examining the impact of air pollution on menstrual health across multiple countries. The research, just published in The Lancet Planetary Health, analyzed data from 2.2 million menstrual cycles tracked in Clue, across 230 cities in the United States, Mexico, and Brazil. The study found that higher concentrations of fine particulate matter (PM2.5) in the air correspond with increased frequency of menstrual cycle irregularities.
While air pollution research has traditionally focused on respiratory or cardiovascular effects, impacts specific to women's health have been largely overlooked— a reflection of the persistent gender health gap in scientific research. This study brings women's health into focus, revealing how environmental factors influence menstrual cycles in unexpected ways, while also demonstrating that when researchers examine sex differences, they can uncover critical health effects that might otherwise remain invisible.
Long-term Pollution Exposure Shows Measurable Effects on Menstrual Health
Specifically, the study found that:
Long-term exposure to higher levels of PM2.5 is associated with a higher percentage of abnormal menstrual cycles, particularly longer cycles, a potential sign of disrupted endocrine and reproductive functioning
While short-term pollution exposure did not show immediate effects, PM2.5 exposure in prior cycles appeared to affect cycle regularity later
The study demonstrated that data from cycle tracking apps can be used to answer important questions on the impact of environmental factors on menstrual and reproductive health
"Menstrual cycle length and variability are a vital indicator of women's health. Research has shown that highly variable menstrual cycles can be associated with an increased risk of premature mortality, cardiovascular disease, type 2 diabetes, cancer, and infertility. The impacts of pollution on menstrual cycle length have been understudied, as few epidemiologic cohorts track menstrual cycle information." - Priyanka deSouza, PhD, MSc, MBA, MTech.
"This study gives us a unique look at how air pollution might affect menstrual cycle length in three different countries. The researchers used data from the Clue app to evaluate long and short cycles in the same person, in relation to air pollution levels in their city. The results suggest a link between PM2.5 (a type of air pollution) and cycle length. PM2.5 is already known to harm human health, especially the heart and lungs. This study shows that it may also affect ovulation and menstrual health." - Shruthi Mahalingaiah, MD, MS, Harvard T. H. Chan School of Public Health and Massachusetts General Hospital.
How Clue's Tracking Technology Can Advance Reproductive Health Science
Rather than relying on retrospective self-reporting as previous studies have done, the research for this study utilized longitudinal cycle tracking data from Clue users, combined with satellite measurements of air pollution levels. This study underscores the power of digital health tools, such as the Clue app, to surface meaningful population-level patterns—especially in areas where traditional research has fallen short.
"Dealing with personal and sensitive data always poses ethical challenges. In this study we were very careful in dealing with such data sets, but we were able to highlight how environmental stressors can have such deep and personal effects," says Fábio Duarte, of MIT Senseable City Lab.
"Clue is helping close the gender health gap by making large-scale research into women's health faster and more feasible than ever before," said Amanda Shea, Fractional Chief Science Officer at Clue. "By analyzing millions of de-identified cycles tracked in the app alongside environmental data, we've taken a new approach to exploring how external factors like pollution might influence reproductive health. This kind of research offers people meaningful insights into their bodies, helping them recognize patterns earlier and make more informed decisions about their health."
Further Research and What Women Can Do
This research builds on prior toxicological and epidemiologic work linking air pollution to reproductive outcomes like preterm birth and infertility, but fills a critical gap by focusing on menstrual health—an under-researched indicator of overall well-being. These findings reinforce calls for improved air quality standards and environmental justice for communities most at risk.
While further research is needed to confirm these effects and better understand the biological mechanisms behind them, especially as the climate crisis intensifies and pollution persists, advancing understanding of how environmental factors impact women's health is more important than ever.
For those concerned about air quality's potential impact on their health, Clue's science team recommends that they:
Monitor air quality and limit exposure during high pollution days: In many cities, you can check daily air pollution levels in your area through local environmental agencies or air quality monitoring apps. Limiting outdoor exposure when air pollution levels are high can help protect your health.
Use the Clue app to track your cycle: By tracking your periods and related cycle symptoms over time, you can build a clearer picture of what's typical for your body. Understanding your own patterns makes it easier to spot changes early—so you can take action or seek support when something feels off.
Consult healthcare professionals: Talk to your healthcare provider if you have any concerning cycle changes or are experiencing symptoms that impact your quality of life. Sharing your cycle tracking data can help inform these discussions.
Methodology:
The study analyzed data from 2,220,281 cycles collected between 2016 and 2020 from 92,550 Clue users across 230 cities in the U.S., Mexico, and Brazil. Satellite-derived estimates of PM2.5 concentrations were aggregated at the city level, and cycle-level data were matched to the corresponding PM2.5 exposure.
About the University of Colorado Denver
Millions of moments start at CU Denver, a place where innovation, research, and learning meet in the heart of a global city. We're the state's premier public urban research university with more than 100 in-demand, top ranked bachelor's, master's, and doctoral degree programs. We partner with diverse learners—at any stage of their life and career—for transformative educational experiences. Across seven schools and colleges, our leading faculty inspires and works alongside students to solve complex challenges and produce impactful, creative work. As part of the state's largest university system, CU Denver is a major contributor to the Colorado economy, with 2,000 employees and an annual economic impact of $800 million. To learn more about how CU Denver helps learners meet their moment, visit ucdenver.edu.
About Clue
Clue is the top women-led menstrual and reproductive health app, loved by over 10 million users around the world. With a science-driven approach, Clue enables members to create a powerful personal health record that uses each cycle as a tool to uncover insight into their overall health. From general cycle health education to fertility, pregnancy, menopausal stages, and all changes and choices in between, the Clue app is CE-marked as a Class 1 medical-grade device. Clue regularly partners with researchers from top institutions and universities to help close the data gap and move female health forward. Based in Berlin, Germany, Clue data is protected by the world's strictest data laws (the EU's GDPR) and by Clue's absolute commitment to standing up for the privacy of its users, no matter where they are. For more, visit helloclue.com.
About MIT Senseable City Lab
The mission of the Senseable City Laboratory—a research initiative at the Massachusetts Institute of Technology—is to anticipate these changes and study them from a critical point of view. Not bound by the methodologies of a single field, the Lab is characterized by an omni-disciplinary approach: it speaks the language of designers, planners, engineers, physicists, biologists and social scientists. For more, visit https://senseable.mit.edu/
press@helloclue.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BeautyHealth Surpasses 35,000 Hydrafacial Devices Worldwide Reflecting Growing Consumer Demand for Clinically Proven Skin Health Treatments
BeautyHealth Surpasses 35,000 Hydrafacial Devices Worldwide Reflecting Growing Consumer Demand for Clinically Proven Skin Health Treatments

Yahoo

time32 minutes ago

  • Yahoo

BeautyHealth Surpasses 35,000 Hydrafacial Devices Worldwide Reflecting Growing Consumer Demand for Clinically Proven Skin Health Treatments

Underscores Hydrafacial's leadership and value to providers and consumers Hydrafacial Syndeo Device LONG BEACH, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial™, recently achieved a major milestone with 35,000 Hydrafacial devices installed worldwide, reinforcing its market leadership in the hydradermabrasion category it pioneered. This accomplishment highlights the Hydrafacial treatment's continued global demand, fueled by strong brand awareness, and growing consumer preferences for non-invasive, results-driven skin health treatments. 'With providers delivering approximately 5 million Hydrafacial treatments last year1, our position as one of the most in-demand professional skin health treatments is clear,' said BeautyHealth Chief Executive Officer, Marla Beck. 'For nearly 28 years, Hydrafacial has been a treatment room essential powered by our science-based innovation and portfolio of 175+ patents that deliver the glowing results that clients and providers love. With a global footprint of 35,000 active Hydrafacial devices worldwide, we're empowering our community to meet rising demand for non-invasive aesthetic treatments and inspire skin confidence around the world.' Hydrafacial's success is backed by industry-leading consumer trust and satisfaction, ranking as the second most recognized facial treatment in the U.S.2 with a 96% 'Worth It' rating on RealSelf3, and an industry-leading 52 Net Promoter Score4. As a proven engine for practice growth, Hydrafacial treatments are responsible for driving approximately 7 percent of all new patients to medical spas and aesthetic practices each year.5 This enthusiasm for the brand translates to 1.5 Hydrafacial treatments performed every second around the world.6 The milestone reflects growing beauty trends favoring a natural, effortless look that prioritizes skin health – an aesthetic Hydrafacial treatments are uniquely designed to deliver. The Hydrafacial treatment combines seven powerful skin therapies in one: lymphatic drainage, a gentle peel, pain-free extractions, superficial microdermabrasion, a personalized booster, LED light therapy, and deep hydration. The result is visible skin improvements, a radiant glow, and a renewed boost in confidence – with zero downtime. 'We're grateful to the estheticians, dermatologists, and plastic surgeons who bring the iconic Hydrafacial glow to life every day,' Beck continues. 'Their trust and expertise drive our growth, and we remain committed to supporting them with ongoing innovation where MedTech Meets Beauty. Together, we're delivering real results – and a glow that keeps clients coming back.' To experience the Hydrafacial treatment and discover why consumers and providers alike trust Hydrafacial for radiant, healthy skin, find a provider near you by visiting and follow along on social @Hydrafacial. 1Company Data. 2Ipsos Study 2024. Base: Consumers of the aesthetic and professional beauty category (n=1000); Brand Aided Awareness. Conversion defined as % of respondents who are aware of and have tried a given brand.3RealSelf as of April 2025. 4Consumers of the aesthetic and professional beauty category that have received a Hydrafacial (n=210); 'On a scale of 0 to 10, how likely are you to recommend Hydrafacial to a friend or colleague?'5Guidepoint Qsight - Sales Measurement as of March 2025.6Treatments per second calculation based on 5 million treatments/year, spread across a 40-hour work week, 50 weeks in a year. About The Beauty Health CompanyThe Beauty Health Company (NASDAQ: SKIN) is a medtech meets beauty company delivering millions of skin health experiences every year that help consumers reinvent their relationship with their skin, bodies, and self-confidence. Our brands are pioneers: Hydrafacial™ in hydradermabrasion, SkinStylus™ in microneedling, and Keravive™ in scalp health. Together, with our powerful global community of estheticians, partners, and consumers, we are personalizing skin health for all ages, genders, skin tones, and skin types. We are committed to being ever more mindful in how we conduct our business to positively impact our communities and the planet. Find a local provider at and learn more at or LinkedIn. Forward-Looking StatementsCertain statements made in this release are 'forward looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'estimates,' 'projected,' 'expects,' 'anticipates,' 'forecasts,' 'plans,' 'intends,' 'believes,' 'seeks,' 'may,' 'will,' 'should,' 'future,' 'propose' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside The Beauty Health Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include The Beauty Health Company's ability to execute its business plan; consumers' perception of skin health, skin concerns, and overall beauty trends; the continued relationship amongst Hydrafacial, its providers, and consumers; the ability to place and continue to place delivery systems across various channels and locations; potential litigation involving The Beauty Health Company; changes in applicable laws or regulations; and the possibility that The Beauty Health Company may be adversely affected by other economic, business, and/or competitive factors. The Beauty Health Company does not undertake any obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by Media Contact: Devries Global: jburchette@ Investors: IR@ Source: BeautyHealth A photo accompanying this announcement is available at

Digital Pathology Market Comprehensive Analysis, Trends and Forecast 2025-2033
Digital Pathology Market Comprehensive Analysis, Trends and Forecast 2025-2033

Yahoo

timean hour ago

  • Yahoo

Digital Pathology Market Comprehensive Analysis, Trends and Forecast 2025-2033

Digital Pathology Market Outlook 2025-2033 Luton, Bedfordshire, United Kingdom, June 04, 2025 (GLOBE NEWSWIRE) -- Market Overview The global digital pathology market is undergoing a significant transformation, driven by the increasing prevalence of chronic diseases, especially cancer, and the urgent demand for more accurate and efficient diagnostic solutions. Digital pathology is a technology-driven discipline that involves the acquisition, management, sharing, and interpretation of pathology information in a digital environment. Unlike traditional glass slide-based microscopy, digital pathology enables virtual microscopy by converting glass slides into digital slides, which can be easily stored, accessed, shared, and analyzed on digital platforms. This transition has revolutionized diagnostic workflows, increased laboratory efficiency, and opened new avenues for collaboration, research, and education. Download PDF Brochure: Market Size and Growth Forecast The global digital pathology market was valued at approximately USD 0.65 billion in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 13.1% from 2025 to 2033. By the end of the forecast period, the market is expected to surpass USD 1.97 billion. The growth trajectory is supported by several factors including the rising incidence of cancer, growing need for faster and accurate diagnostic tools, and advancements in digital imaging technologies. Key Market Drivers One of the primary factors propelling the market is the escalating prevalence of cancer and chronic diseases globally. These health challenges demand timely and precise diagnostics, which digital pathology efficiently facilitates. Additionally, the integration of artificial intelligence (AI) and machine learning into digital pathology systems is significantly enhancing diagnostic capabilities by enabling automated image analysis and predictive modeling. Technological advancements such as robotic light microscopy, digital imaging, fiber optic communications, and whole slide imaging have further elevated the utility and performance of digital pathology platforms. Whole slide imaging, in particular, allows high-resolution scanning of entire pathology slides, providing detailed and zoomable images for comprehensive analysis. Market Segmentation Analysis By Type The digital pathology market is segmented into human pathology and veterinary pathology. Human pathology holds the dominant market share, primarily due to the growing number of cancer-related studies and rising collaborations among research institutes, healthcare institutions, and diagnostic labs. Veterinary pathology, while a smaller segment, is gaining traction with increasing digitization in animal health diagnostics. By Product The market comprises various products including devices, scanners, software, communication systems, and storage systems. Among these, the device segment—which includes slide scanners and management systems—holds the largest share. This is attributed to enhanced resolution and improved magnification capabilities, as well as technological innovations such as Z-axis scanning in whole slide imaging. Software solutions are also playing a vital role in image analysis, data management, and remote consultations. By Application Key application areas of digital pathology include drug discovery, disease diagnosis, teleconsultation, and education and training. Disease diagnosis remains the leading application due to the growing burden of chronic illnesses and the need for precision diagnostics. The role of digital pathology in enhancing interdepartmental communication and streamlining diagnostic workflows is significant. Drug discovery is another major application, particularly among pharmaceutical and biotechnology companies utilizing digital platforms for toxicology testing and molecular profiling. By End User End users in the digital pathology market include pharmaceutical and biotechnology companies, hospitals, and academic research institutes. Pharmaceutical and biotechnology companies dominate this segment due to the growing reliance on digital pathology for drug development, personalized medicine, and biopharmaceutical research. Hospitals are increasingly adopting digital pathology to improve diagnostic accuracy and patient outcomes. Academic and research institutions are also leveraging digital platforms for education and collaborative research. Market Segments: Digital Pathology Market Digital Pathology Market By Type, Human Pathology Veterinary Pathology Digital Pathology Market By Product, Device Scanners Software Communication Systems Storage Systems Digital Pathology Market By Application, Drug Discovery Disease Diagnosis Teleconsultation Training Education Digital Pathology Market By End User, Pharmaceutical And Biotechnology Hospitals Academic Research Institutes Digital Pathology Market By Region, North America Europe Asia Pacific South America Middle East And Africa Browse full Report - Regional Insights The market is geographically segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. North America leads the global digital pathology market with over 41% share in 2020. The region's dominance is underpinned by strong R&D investments, supportive government policies, early adoption of advanced imaging technologies, and the presence of leading market players. The U.S. has been at the forefront of digital pathology integration in clinical settings, further supported by favorable reimbursement frameworks and a growing emphasis on cancer screening programs. Asia-Pacific is projected to witness the fastest growth during the forecast period. Factors such as increasing investments in healthcare infrastructure, growing incidence of cancer, and the adoption of digital solutions in diagnostics are contributing to the region's rapid market expansion. Countries like China, India, and Japan are seeing increasing government and private sector initiatives to modernize pathology labs. Europe holds a significant share of the market as well, benefiting from rising adoption of telemedicine, integration of digital platforms in healthcare systems, and strong presence of research institutions. South America and Middle East & Africa represent emerging markets with growing awareness and gradual adoption of digital pathology. These regions are anticipated to witness steady growth as healthcare systems evolve and digital technologies become more accessible. Competitive Landscape The digital pathology market is highly competitive and features a number of key players employing various strategic initiatives to strengthen their market presence. Leading companies include: 3DHISTECH Hamamatsu Photonics Leica Biosystems Koninklijke Philips Apollo Enterprise Imaging XIFIN Ventana Medical Systems Visiopharm Corista Huron Digital Pathology These players are focusing on product innovation, partnerships, mergers and acquisitions, and geographic expansion to cater to the growing demand. For instance, the introduction of affordable scanners aimed at private pathology practices is an emerging trend likely to democratize access to digital pathology solutions. Emerging Trends and Opportunities Emerging trends in the digital pathology market include the increased integration of AI algorithms for image analysis, development of cloud-based solutions for slide storage and sharing, and the rise of hybrid models combining AI with human expertise. The growing need for remote diagnostics and teleconsultation has been accelerated by the COVID-19 pandemic, making digital pathology an essential component of modern healthcare infrastructure. Additionally, the rising demand for personalized medicine and precision oncology is pushing pharmaceutical companies to invest more in digital pathology tools. As biobanking and molecular diagnostics gain momentum, digital platforms that can handle complex data and provide real-time insights are increasingly preferred. Challenges and Risk Factors Despite strong growth potential, the market faces certain challenges. High initial setup costs, lack of standardization, data security concerns, and limited skilled professionals are among the key barriers to widespread adoption. Moreover, regulatory hurdles and concerns about digital slide image quality and diagnostic equivalency with traditional microscopy continue to pose risks. Buy Now : Recent Developments : 1. 3DHISTECH 3DHISTECH has been at the forefront of digital pathology innovations, introducing several advancements in 2024: P480 2nd Generation Slide Scanner: In April 2024, 3DHISTECH launched the P480 2nd Gen, an upgraded version of its flagship slide scanner. This new model offers enhanced features, making it a vital tool for modern digitized laboratories. 3DView Software: The company introduced 3DView, a software application capable of preparing 3D reconstructions from 2D serial sections and displaying microCT images in 3D formats. MDSAP Certification: In January 2024, 3DHISTECH achieved the Medical Device Single Audit Program (MDSAP) certification for Canada and Australia, demonstrating compliance with ISO 13485 standards and expanding opportunities in these markets. Collaborations: The company partnered with Quantmetry to utilize its SimpleSlideInterface and collaborated with Epredia to open a Pathology Innovation Incubator aimed at accelerating advancements in cancer diagnostics. 2. Philips Philips has made significant strides in digital pathology through strategic collaborations and technological advancements: Collaboration with AWS: In March 2024, Philips expanded its collaboration with Amazon Web Services (AWS) to scale digital pathology solutions in the cloud. This partnership aims to enhance diagnostic capabilities and improve productivity by integrating Philips' digital pathology expertise with AWS's scalable cloud solutions. Partnership with French Hospitals: Philips partnered with Saint-Joseph Hospital and Marie-Lannelongue Hospital in France to integrate digital pathology into their enterprise imaging workflows. This integration allows care teams to access comprehensive diagnostic information, enhancing personalized cancer care. IntelliSite Pathology Solution 5.1: Philips received 510(k) clearance for its IntelliSite Pathology Solution 5.1, signaling a significant advancement in digital pathology solutions. 3. Leica Biosystems Leica Biosystems has introduced several innovations to enhance digital pathology workflows: Aperio GT 450 Enhancements: In January 2025, Leica Biosystems unveiled significant enhancements to its Aperio GT 450 Digital Pathology Scanner, improving performance and reliability for digital pathology applications. Partnership with Molecular Instruments: The company announced a partnership with Molecular Instruments to enable fully integrated RNA-ISH using the BOND RX and BOND RXm research staining systems, facilitating advanced molecular pathology research. HistoCore CHROMAX Workstation: Leica Biosystems launched the HistoCore CHROMAX Workstation in January 2025, advancing its staining and coverslipping portfolio to optimize laboratory workflows. 4. Visiopharm Visiopharm has been active in developing AI-driven solutions for digital pathology: End-to-End Digital Pathology Workflow: In collaboration with Agilent Technologies, Proscia, and Hamamatsu Photonics, Visiopharm announced a comprehensive end-to-end digital pathology solution at USCAP 2023. This solution integrates Visiopharm's AI-driven precision pathology software with Agilent's automated staining solutions and Hamamatsu's whole slide imaging systems. Expanded Distribution Agreement: Visiopharm and Agilent expanded their distribution agreement to include the US and Canada, broadening access to their integrated digital pathology solutions. 5. Hamamatsu Photonics Hamamatsu Photonics has contributed to digital pathology advancements through strategic partnerships: Partnership with Agilent: Hamamatsu partnered with Agilent Technologies to incorporate their NanoZoomer® Slide scanner systems into Agilent's end-to-end digital pathology solution. This collaboration aims to provide high-resolution digital data through high-speed scanning, enhancing diagnostic quality and efficiency. Comprehensive Digital Pathology Solution: As part of the collaboration with Agilent, Visiopharm, and Proscia, Hamamatsu's imaging systems play a crucial role in the open, scalable digital pathology workflow designed to accelerate breakthroughs in precision medicine. This report is also available in the following languages : Japanese (デジタル病理学市場), Korean (디지털 병리학 시장), Chinese (数字病理学市场), French (Marché de la pathologie numérique), German (Markt für digitale Pathologie), and Italian (Mercato della patologia digitale), etc. Request Sample Pages : More Research Finding – Pathology Devices Market The pathology devices market is set to reach an estimated value of $15.6 billion in 2024. This sector is expected to experience significant growth, with a projected market value of approximately $27.2 billion by 2034, indicating a robust Compound Annual Growth Rate (CAGR) of about 6.0% during the forecast period from 2025 to 2034. Clinical Digital Pathology Market The global clinical digital pathology market is projected to reach approximately $6.2 billion in 2024, with expectations to grow significantly during the forecast period from 2025 to 2034, potentially reaching around $13.5 billion. This reflects a robust Compound Annual Growth Rate (CAGR) of about 8.5%. Laboratory Information Systems Market The global Laboratory Information Systems (LIS) market is valued at approximately $3.5 billion, reflecting robust demand driven by the increasing need for efficient data management in laboratories. The projected market value is expected to reach about $6.2 billion by 2034, showcasing significant growth potential. This implies a Compound Annual Growth Rate (CAGR) of approximately 6.0% from 2025 to 2034. Cellular Pathology Market he cellular pathology market is projected to reach a value of approximately $23 billion in 2024, driven by increasing healthcare spending and advancements in diagnostic technology. Over the forecast period from 2025 to 2034, the market is expected to expand significantly, with an estimated compound annual growth rate (CAGR) of 9.2%, potentially reaching around $56 billion by 2034. Artificial Intelligence In Pathology Market The global market for artificial intelligence (AI) in pathology is valued at approximately $1.2 billion. The market is projected to grow significantly, reaching an estimated value of $4.5 billion by 2034, fueled by advancements in technology and increasing adoption of AI solutions in healthcare settings. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is anticipated to be around 15.1%. AI-Based Digital Pathology Solutions Market Global AI-Based Digital Pathology Solutions Market Size Was Estimated At USD 24.1 Billion In 2023 And Is Projected To Reach USD 34.9 Billion By 2032, At CAGR Of 8.60% (2024-2032) Anatomic Pathology Market The global anatomic pathology market is projected to reach USD 58.90 billion by 2029 from USD 32.58 billion in 2022, at a CAGR of 6.8% from 2023 to 2029. Breast Cancer Liquid Biopsy Market The global breast cancer liquid biopsy market is expected to grow at 24% CAGR from 2022 to 2029. It is expected to reach above USD 1548.29 million by 2029 from USD 343.48 million in 2022. Neurodiagnostics Market The global neurodiagnostics market is expected to grow at 7.4% CAGR from 2019 to 2028. It is expected to reach above USD 11.6 billion by 2028 from USD 6.1 billion in 2019. CD160 ELISA Kit Market The global neurodiagnostics market is expected to grow at 7.4% CAGR from 2019 to 2028. It is expected to reach above USD 11.6 billion by 2028 from USD 6.1 billion in 2019. Angiopoietin 2 ANG2 ELISA Kit Market The global Angiopoietin 2 (ANG2) ELISA Kit market is anticipated to reach a valuation of approximately $210 million in 2024, with projections suggesting it may grow to around $415 million by 2034. This growth indicates a Compound Annual Growth Rate (CAGR) of about 7.2% during the forecast period from 2025 to 2034. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market The market for Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (G-CSF) is projected to reach approximately USD 4.1 billion in 2024, driven by increasing incidences of hematological malignancies and the rising demand for effective supportive care in cancer treatment. The market is expected to expand at a robust Compound Annual Growth Rate (CAGR) of 8.5% from 2025 to 2034, potentially reaching around USD 9 billion by the end of this forecast period. Human Papillomavirus Vaccine Types 16 18 Market The global market for Human Papillomavirus (HPV) vaccines, particularly those aimed at preventing types 16 and 18, is valued at approximately $3 billion. The market is projected to reach around $5 billion by 2034, reflecting heightened awareness of HPV-related health risks and increased vaccination initiatives worldwide. Beta-Human Chorionic Gonadotropin HCG ELISA Test Kit Market The Beta-Human Chorionic Gonadotropin (HCG) ELISA Test Kit market is anticipated to reach a value of approximately $450 million in 2024. This market is projected to grow significantly, with expected values of around $700 million by 2034, reflecting a Compound Annual Growth Rate (CAGR) of approximately 5.2% during the forecast period from 2025 to 2034. Human Chorionic Gonadotropin Test Kit Market The Human Chorionic Gonadotropin (hCG) test kit market is estimated to reach a value of approximately $1.5 billion in 2024, driven by increasing demand for early pregnancy detection and fertility monitoring. The market is projected to grow significantly, with an anticipated value of around $3 billion by 2034, reflecting a robust compound annual growth rate (CAGR) of approximately 8.4% during the forecast period from 2025 to 2034. Calcitonin ELISA Test Kit Market The global market for Calcitonin ELISA Test Kits is valued at approximately $150 million in 2024 and is projected to reach around $220 million by 2034, reflecting a robust growth trajectory. This results in a Compound Annual Growth Rate (CAGR) of roughly 4.5% from 2025 to 2034. Anti-parasite Products Market The global anti-parasite products market is valued at approximately $12 billion, driven by increasing awareness of parasitic infections in both humans and animals. The market is projected to reach around $18 billion by 2034, reflecting a compound annual growth rate (CAGR) of approximately 4.8% during the forecast period of 2025 to 2034. Human Serum Albumin Market The global Human Serum Albumin (HSA) market is projected to reach approximately USD 7.8 billion in 2024, driven by increasing demand in therapeutic applications, especially for liver diseases, shock, and burns treatment. Over the forecast period from 2025 to 2034, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of around 6.6%, potentially reaching USD 13.2 billion by 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Sound, Spirit, and Celebration: Maejor, Jim James, and Vic Mensa Lead the Musical Heartbeat of Psychedelic Science 2025
Sound, Spirit, and Celebration: Maejor, Jim James, and Vic Mensa Lead the Musical Heartbeat of Psychedelic Science 2025

Yahoo

timean hour ago

  • Yahoo

Sound, Spirit, and Celebration: Maejor, Jim James, and Vic Mensa Lead the Musical Heartbeat of Psychedelic Science 2025

• Music Is the Bridge: Frequencies, Visions, Creativity Session at PS2025 Explores the Role of Sound in Emotional Integration, Brainwave Regulation, and Therapeutic Breakthroughs • Reggie Watts, Flying Lotus, Maejor, Jim James, and Vic Mensa Live Performances and Events Bring the Healing Power of Music to Life Beyond the Convention Center DENVER, June 04, 2025 (GLOBE NEWSWIRE) -- Psychedelic Science, the premier global gathering for psychedelic research, medicine, policy, and culture hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), has unveiled an inspiring lineup of musical visionaries headlining both the keynote stage and immersive live events at Psychedelic Science 2025 (PS2025) in Denver, Colorado. Keynote: Sound, Frequencies, and Emotional AlchemyGrammy-nominated artist and sound healing innovator Maejor (Brandon Green) and rapper and activist Vic Mensa will join forces in a powerful keynote session titled Music Is the Bridge: Frequencies, Visions, Creativity. On Wednesday, June 18 (2:30–3:15 PM MDT) in the Bluebird Ballroom 1A – these artists will explore how sound becomes medicine and melody a tool for transformation. Maejor—known for mastering albums at 432 Hz—shares how scientifically tuned music fosters deep harmony and Vic Mensa will speak to how medicine journeys have influenced his music, activism, and sense of ancestral connection. 'Music is a universal language. It resonates deeply, brings people together, and creates space for healing and self-discovery. That is why we use it as a bridge, not just to inspire but to share resources, support community, and spark curiosity. This keynote features some of the most visionary artists of our time, showing how music can be a catalyst for healing and radical creativity. And beyond the stage, the energy continues throughout the week as Denver becomes a living soundscape, with performances by Flying Lotus, Reggie Watts, Vic Mensa, and more.'—Devon Phillips, Community & Partnerships Officer More Music, More Magic Across DenverBut the magic doesn't stop at the Colorado Convention Center. Throughout the week, Denver transforms into a vibrant soundscape with unforgettable performances and immersive events: MAPS Psychedelic Science Kickoff Party with Flying Lotus & Reggie Watts Live, and Jim James and Vic Mensa DJ Sets: My Morning Jacket's Jim James and Vic Mensa will both host special DJ sets, setting the tone for an unforgettable evening ahead of Flying Lotus & Reggie Watts Live at the Mission Ballroom on Tuesday, June 17. Presented by Good Trip Studios, producers of Have a Good Trip on Netflix, this kickoff promises an electrifying fusion of music, art, and community. Tandava with Poranguí & Savej: Join Tandava Retreats on Tuesday, June 17, at Cervantes for a night of tribal rhythms, global healing sounds, and comedy by Dennis Walker (the Mycopreneur). Good Trip Presents: Conversation + Listening Party with Vic Mensa (Wednesday, June 18 at The PORTAL Dome): An intimate, 360° experience with music, film, and deep conversation. Join rapper and activist Vic Mensa for a Q&A and listening session, blending beats and dialogue in the immersive PORTAL Dome. Moderated by Donick Cary (Have a Good Trip, The Simpsons). Blind Melon with Ridgeliners Live at Cervantes' Masterpiece Ballroom (Thursday, June 19): Experience an unforgettable night of alternative rock as Blind Melon brings their neo-psychedelic sound to Denver's Cervantes' Masterpiece Ballroom on Thursday, June 19. Known for their 1993 hit "No Rain," Blind Melon continues to captivate audiences with their unique blend of rock and soulful melodies. Good Trip Presents: Conversation, Q&A, and Listening Party of My Morning Jacket's New Album 'Is' with Jim James (Friday, June 20 at The PORTAL Dome) invites you to an intimate, 360° experience that blends music, film, and deep conversation. Join My Morning Jacket frontman Jim James for a Q&A and exclusive listening session for the band's new album, 'is' in the immersive PORTAL Dome. Moderated by Donick Cary (Have a Good Trip, The Simpsons). LSZEE: LSDREAM & CloZee Live at Mission Ballroom (June 19–22): A bass-fueled collaboration that fuses psychedelic rhythms and global beats for an auditory adventure. Ecstatic Dance Denver (Sunday Morning Dance Party – Sober, Safe, and Sacred): No booze. No cell phones. No small talk. Just pure movement with Denver's top EDM DJs. Other highlights include immersive series like Shroomski Melt, Queer Magic 2, and more community gatherings. Visit to view the full schedule, register for workshops, and explore hotel and travel options. Workshop spaces are limited and available on a first-come Psychedelic SciencePsychedelic Science 2025 (PS2025), hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), is the world's leading psychedelic conference. Returning to the Colorado Convention Center in Denver from June 16-20, 2025, this five-day event brings together a global community of scientists, therapists, policymakers, cultural leaders, and advocates to explore the forefront of psychedelic research, therapy, and culture. Facilitated by Superfly, known for producing iconic events such as Bonnaroo and Outside Lands, PS2025 will feature expert speakers; hands-on workshops; community events with art, music, and mindfulness activities; and scholarship opportunities to support broad participation. Since its inception in 2010, the Psychedelic Science conference series has fostered knowledge-sharing, collaboration, and community-building within the psychedelic ecosystem. Join thousands of attendees as we explore the transformative potential of psychedelics and shape the future of mental health, policy, and cultural understanding. For more information and registration details, visit and follow us on X, Instagram, LinkedIn, and Facebook. ABOUT MAPSFounded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS' conference flagship, Psychedelic Science, has been the leading convening of the psychedelic community since 2010. MAPS incubated Lykos Therapeutics, a drug-development public benefit company, and the Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $150 million to advance research, change drug policy, and evolve education in the field of psychedelics. CONTACTmedia@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store